| Code | CSB-RA005508MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar referenced to the antibody described in patent WO2017096163A1, targeting both CLDN6 (claudin-6) and CLDN9 (claudin-9). CLDN6 and CLDN9 are tight junction proteins minimally expressed in normal adult tissues but aberrantly reactivated in various malignancies. CLDN6 is highly expressed in ovarian, endometrial, testicular, gastric, and lung cancers, where it promotes tumor progression through PI3K/AKT and EGFR/mTOR pathways, driving cell proliferation, matrix degradation via MMP activation, and epithelial-mesenchymal transition. CLDN9, which shares high sequence homology with CLDN6, enhances cancer cell migration through cytoskeletal rearrangement and activation of MAPK and Tyk2/STAT3 pathways. Co-expression of CLDN6 and CLDN9 in endometrial cancer correlates with significantly worse prognosis and increased metastatic potential. The reference antibody is designed to simultaneously target both CLDN6 and CLDN9, addressing their complementary roles in tumor invasion and metastasis. This biosimilar provides researchers with a valuable tool for investigating claudin-mediated oncogenic pathways, studying tight junction dynamics in cancer, and exploring dual-target therapeutic strategies in preclinical solid tumor models. It supports research into EMT mechanisms, cell adhesion biology, and the synergistic effects of CLDN6/CLDN9 co-expression in tumor progression.
There are currently no reviews for this product.